$VIVS

VivoSim Labs (Nasdaq: VIVS) announced it is expanding its human tissue platform to include efficacy testing services for liver and intestinal disease models, using patient-derived cells. The move aims to help drug developers assess candidate compounds before clinical trials, addressing the common issue of lack of efficacy. The company's models have shown success in identifying disease mechanisms and drug effects.

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 13, 2026, Organovo, Inc. (“Organovo”), a wholly-owned subsidiary of VivoSim Labs, Inc. (the “Company”), entered into a Second Amendment to Amended and Restated Lease (the “Amendment”) with San Diego Inspire 2, LLC (

VivoSim Labs (VIVS) welcomes FDA's updated regulations allowing greater use of non-animal testing methods. The rule replaces 'animal tests' with 'nonclinical tests,' benefiting VivoSim's 3D human cellular models. VivoSim's models can identify drug safety risks earlier, reducing development costs. The company expects accelerated adoption of its NAM models following the FDA's roadmap.

VivoSim (VIVS) reported its NAMkind(TM) Liver model achieved 91% predictive accuracy, 90% sensitivity, and 95% specificity in drug-induced liver injury tests. Its VitroSense(TM) AI platform showed up to 96% accuracy in predicting drug-induced diarrhea. The company plans to develop a rat liver model to bridge animal and human data, aiming for regulatory and pharmaceutical adoption. Key milestones include FDA qualification and broader industry use.

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2026, VivoSim Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting

VivoSim Labs (NASDAQ: VIVS) presented data at EUROTOX 2026 showing its NAMkind™ platforms can predict drug toxicity in liver and gastrointestinal systems for small molecules and ADCs. The data ranked clinical safety risks and distinguished payload- and linker-dependent toxicities in ADCs, positioning VivoSim in the growing market for human-relevant predictive toxicology.

VivoSim Labs (VIVS) presented data at EUROTOX 2026 showing its NAMkind™ platforms can predict drug toxicity in liver and gut models. The liver platform maintains viability for 28 days, while intestinal models preserve barrier function for three weeks. Studies ranked safety risks for small molecules and differentiated ADC toxicities, with trastuzumab deruxtecan showing higher hepatotoxicity. The stock declined 4.18% post-announcement, trading at $0.26 with heavy volume.

VivoSim Labs (VIVS) is developing a rat liver model to complement its human liver model, aiming to improve drug toxicity predictions. This could help pharma companies make earlier decisions on drug candidates, potentially expanding VIVS's NAMkind(TM) platform's use. The FDA's push for human-relevant testing may provide a favorable backdrop. VIVS expects 500%+ fiscal 2027 revenue growth from its NAM-based business.

GoPro (GPRO) to merge with Starman Optical for $285M, expanding into AI data centers. Fly-E (FLYE) reports $19.1M revenue, growing in electric mobility. Cellyan (HKPD) operates in cross-border pharmaceutical e-commerce. VivoSim (VIVS) has $10.1M cash, aided by a $5M milestone from Eli Lilly (LLY).

Lialin Tony Serge (Chief Commercial Officer) purchased 10,000 shares of VivoSim Labs, INC. (VIVS) at $0.28 on 2026-08-31.